Executive Overview: 2025 as a Breakthrough Year

The antibody–drug conjugate (ADC) field reached a defining inflection point in 2025. According to the Beacon ADC database maintained by Hanson Wade, a total of 2,334 distinct antibody-based drug conjugates were tracked globally as of January 5, 2026—representing a 20% year-over-year (YoY) increase in traditional ADCs and an extraordinary 88% YoY increase in novel ADC formats.

Most strikingly, 130 new ADC candidates progressed into clinical development in 2025, a 49% increase over the prior year and the highest single-year clinical entry figure ever recorded. Alongside this volume surge, the field witnessed four first-ever drug approvals—telisotuzumab vedotin (FDA), trastuzumab rezetecan (NMPA), becotatug vedotin (NMPA), and trastuzumab botidotin (NMPA)—plus the reinstatement of belantamab mafodotin across three major regulatory jurisdictions.

Pipeline Growth and Drug Status Dynamics

Among the 2,334 tracked drug conjugates, the current active clinical-stage population stands at approximately 17% of the total pipeline, with 36% in active preclinical development. Roughly 41% have been classified as not active or deprioritized—a proportion that increased notably following Beacon's 2025 review of its Not Active Drug policy, which resulted in a higher volume of reclassifications.

In terms of drug status changes during 2025, approximately 26% of all tracked drugs were newly added, 57% remained unchanged, and 17% were updated. Of the updated drugs, 80% reflect reclassifications from active to not active, primarily due to competitive pressures and strategic de-prioritization rather than clinical failure.

Newly Approved Drugs in 2025

Four ADCs achieved first-ever regulatory approval in 2025:

Additionally, belantamab mafodotin regained approval across the US, Europe, and Japan following additional clinical evidence addressing its prior ocular toxicity concerns, underscoring how second-generation ADC management strategies can rehabilitate molecules with early safety challenges.

Clinical Development Progression

Among the 108 drugs that advanced to higher development phases in 2025, 43% progressed from preclinical to clinical stages, and 18% advanced to later clinical phases. A notable trend is the initiation of Phase 4 studies by multiple approved ADCs to assess long-term safety and real-world effectiveness—an indicator of the field's overall maturation.

Modality Evolution: Beyond Traditional ADCs

The structural composition of the ADC landscape is undergoing a fundamental shift. While traditional ADCs still constitute the largest segment (1,770 drugs, 75% of the total), novel conjugate modalities have collectively reached 595 drugs, growing at 88% YoY versus 20% for traditional ADCs.

Bispecific ADCs: Strong Momentum With Engineering Challenges

BsADCs represent the second-largest modality and demonstrated particularly strong 2025 performance, with a 65% YoY increase in drug count and 10 assets newly entering clinical development. Eight Phase 3 trials were initiated, driven by encouraging clinical readouts that highlight the potential for improved efficacy and reduced resistance via dual-targeting strategies.

However, roughly a quarter of BsADC candidates were discontinued or rendered inactive in 2025, underscoring the persistent manufacturing and stability challenges inherent to bispecific construct design. The acquisition of Merus by Genmab for $8 billion in September 2025—largely driven by Merus's proprietary Multiclonics® bispecific platform—signals the premium that the market places on validated bispecific antibody engineering capabilities.

AOCs: Regulatory Fast-Track Acceleration

AOCs target rare diseases such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy Type 1 (DM1), and Facioscapulohumeral Muscular Dystrophy (FSHD)—disease areas historically underserved by traditional ADC programs. Their rapid advance toward regulatory submissions (four candidates approaching BLA/MAA filing windows) is supported by expedited designation schemes in both the US and China, as well as a macro-trend of investment shifting from mRNA-based therapies toward precision oligonucleotide delivery platforms.

The $12 billion acquisition of Avidity Biosciences by Novartis in October 2025—which brought three AOC candidates at the registrational stage—confirms institutional validation of this modality as a commercially viable therapeutic class.

Dual-Payload ADCs: Clinical Translation at a Pivot Point

Dual-payload ADCs are engineered to overcome mechanisms of resistance to single-payload designs by co-delivering two cytotoxic agents via a single targeting construct. With KH815 and IBI3020 advancing into Phase 1 in 2025, and HMBD-802 preparing for Phase 1 initiation in early 2026, the field is entering a critical window: initial clinical readouts from these candidates will define the modality's viability and shape the investment thesis for the next generation of ADC design.

Target Landscape: Emerging Antigens and Dual-Targeting Trends

Single-Target Dominance and Emerging Challengers

HER2, TROP2, B7-H3, and CLDN18.2 continue to dominate the single-targeting ADC field. HER2 alone accounts for the largest cohort of clinically active ADCs, while TROP2 has become the defining target of the NSCLC ADC space following the commercial success of multiple deruxtecan- and exatecan-class conjugates.

The defining emerging target of 2025, however, was CDH17—growing from 6 to 22 drug candidates over the course of the year. The initial surge was catalyzed at the 2025 AACR Annual Meeting, where seven new CDH17-targeting assets were identified simultaneously. CDH17 exhibits high and preferential expression in tumor cells relative to normal tissues—particularly across gastrointestinal malignancies—offering an attractive therapeutic window with limited off-target toxicity risk. With no CDH17-directed therapy yet approved, and 10 candidates actively enrolled in clinical studies by year-end, this antigen represents one of the most significant competitive opportunities in the current ADC target landscape.

DLL3 also demonstrated renewed momentum in 2025, with six additional DLL3-targeting assets entering development—building on the clinical success of tarlatamab, a DLL3/CD3-targeting bispecific antibody. Notably, zocilurtatug pelitecan advanced to Phase 3 evaluation, anchoring DLL3 as a mature clinical target with demonstrated competitive viability.

Dual-Target Combinations: c-MET × EGFR Consolidates Leadership

Within bispecific ADCs, the c-MET × EGFR target pair continued to lead with 24 drug candidates as of early 2026. The combination exploits synergistic biology and consistent co-expression patterns within the tumor microenvironment, reducing resistance risk and enhancing therapeutic indices. Nine c-MET × EGFR BsADC candidates have entered clinical trials, with tilatamig samrotecan—now in Phase 2 per AstraZeneca's pipeline—as the most advanced.

A notable newcomer in dual-targeting is the Nectin-4 × TROP2 pair, with all five currently tracked candidates entering the market in 2025. AK146D1 (Akeso Biopharma) and AVZO-103 (Avenzo Therapeutics) both initiated clinical studies, marking a deliberate effort to leverage established Nectin-4 and TROP2 biology within a bispecific ADC framework to address resistance patterns seen with monospecific agents targeting either antigen alone.

Payload and Conjugation Technology Trends

Payload Class Distribution

The payload landscape remains highly concentrated, with topoisomerase I (topo-1) inhibitors and tubulin inhibitors collectively dominating approximately 80% of clinical licensing agreements. Within topo-1 inhibitors, exatecan and its analogues represent the dominant payload class, accounting for 41 ADC candidates in active clinical trials—substantially outnumbering DXd (a structurally related derivative) and traditional MMAE-class agents.

Topo-1 inhibitors achieved 50% YoY growth in total volume in 2025, driven in part by the commercial success of deruxtecan-ADC combinations and the proliferation of exatecan-conjugated next-generation molecules. However, this concentration also creates a strategic imperative: as topo-1 inhibitor-based ADCs accumulate in both development pipelines and commercial markets, differentiation through alternative payload mechanisms becomes increasingly critical for competitive positioning.

Emerging Payload Mechanisms

Beyond the dominant classes, a small but strategically important cohort of novel payload mechanisms are entering clinical evaluation:

Glucocorticoid-based payloads have advanced three candidates into the clinic over the past three years despite earlier setbacks, reflecting persistent industry interest in their immunomodulatory potential—including in non-oncology indications such as autoimmune disease (e.g., AbbVie's ABBV-319).

Conjugation Technology: Site-Specific Approaches Gaining Ground

Although the majority of conjugation methods in active clinical programs remain undisclosed, site-specific conjugation technologies have shown consistent and significant growth over the past three years in drugs entering the clinic. Site-specific approaches—including transglutaminase-mediated conjugation, sortase-based ligation, unnatural amino acid incorporation, and engineered cysteine conjugation—offer tighter drug-to-antibody ratio (DAR) control, improved homogeneity, and enhanced pharmacokinetic predictability relative to non-site-specific methods.

The increasing adoption of site-specific conjugation across newly entered clinical programs suggests that manufacturers are moving beyond proof-of-concept—treating conjugation precision as a manufacturing standard rather than a differentiating feature.

Clinical Trial Landscape

As of the January 2026 dataset, Beacon ADC tracks 3,423 total trial records. In 2025, 791 new trials were added—with the majority being Phase 1 or Phase 1/2 studies—while 581 existing trials received updates and 2,051 remained unchanged.

Trial Activity and Recruitment Dynamics

Among updated trial records, approximately 30% transitioned to an "active not recruiting" status, ~25% each moved to unknown or recruiting status, 23% reached completion, and 14% were discontinued. The number of completed trials in 2025 was 24% lower than in 2024, while discontinuation and recruitment rates remained broadly comparable year-over-year—suggesting stable operational execution despite a more competitive enrollment environment.

Top ADCs by Trial Volume

Sacituzumab tirumotecan claimed the top position in 2025 with 64 associated trials—more than doubling from 24 in 2024. This acceleration reflects the drug's trajectory from its November 2024 approval for triple-negative breast cancer through subsequent FDA Breakthrough Therapy designation for EGFR+ NSCLC in March 2025, and NMPA Breakthrough Therapy designation for first-line NSCLC in early 2026.

Trastuzumab deruxtecan (T-DXd) maintained its position with 31 trials, while disitamab vedotin—the 2024 leader—dropped to third with 33 trials from 46 in 2024, reflecting the competitive dynamics of the HER2/TROP2 space in China.

Trial Discontinuation: Principal Drivers

Fifty-seven trials were discontinued in 2025, with 77% terminated, 16% withdrawn, and 7% suspended. Traditional ADCs accounted for 93% of discontinuations. The predominant reported reasons were sponsor decisions (13 trials), business or strategic considerations (10 trials), and recruitment issues (10 trials). Efficacy or safety-related terminations accounted for only 7 of the 57 discontinued trials—consistent with the finding that market saturation and competitive pressure are now the primary drivers of pipeline attrition rather than clinical failure per se.

Deal Dynamics and Commercial Landscape

Over the five-year period from 2021 to 2025, the ADC space generated 913 transactions totaling $368 billion in announced deal value. However, the trajectory within this period is nonlinear: deal values peaked in 2023 at $145 billion, followed by a contraction in 2024, and a partial recovery in H2 2025 driven by two major acquisitions.

Structural Shift Toward Late-Stage De-Risked Dealmaking

The most structurally significant trend in 2025 deal activity is the collapse of ADC-related financing—from a $33 billion peak in 2023 to just $3 billion in 2025. This decline does not reflect diminished investor interest in the ADC class; rather, it signals a fundamental reorientation of capital allocation away from early-stage, high-risk financing toward late-stage M&A and licensing agreements centered on validated technologies or clinical-stage programs.

As a result, companies with differentiated platforms (site-specific conjugation, bispecific engineering, novel payload mechanisms) or clinical programs with Phase 2+ readouts are now the primary targets of institutional capital—while early-stage companies without clear technological differentiation face significantly constrained financing access.

Landmark 2025 Acquisitions

Both acquisitions underscore a consistent strategic theme: large pharmaceutical companies are paying significant premiums for platform companies with differentiated conjugation technologies and late-stage clinical assets—not merely for individual programs.

Geographic Distribution of Development Activity

The USA continues to lead with 559 biopharma companies active in the ADC space (+31% from 2024), followed by China with 247 companies (+36%) and South Korea with 91 (+47%). Notably, South Korea and Japan showed the steepest proportional growth rates among major ADC hubs, each increasing by approximately 50%, reflecting the accelerating global diversification of ADC R&D capacity.

Regulatory Milestones and Assets to Watch

Trastuzumab deruxtecan generated the greatest volume of regulatory activity in 2025 with 24 discrete regulatory updates across multiple jurisdictions and indications, reinforcing its status as the benchmark ADC platform in the current era. Datopotamab deruxtecan and sacituzumab tirumotecan followed with 19 and 11 updates respectively.

Regulatory activity types in 2025 were dominated by trial approvals (48% of all regulatory events), drug designations (13%), and regulatory interactions (13%), with drug approvals and submission-related activities each contributing approximately 4–7%.

Key Assets to Watch in 2026–2027

Intellectual Property: Maturation and Strategic Diversification

The ADC patent landscape encompasses 239,140 total patents, of which 53% cover the five core ADC therapeutic classes (traditional ADC, bispecific ADC, dual-payload ADC, AOC, DAC). In 2025, 17,162 ADC-specific patent applications were published—an 11.4% YoY increase—with 56% belonging to unique patent families, indicating a continued strong influx of novel inventions alongside global IP protection strategies.

Innovation Momentum: Novel Modalities Dominate New Families

Bispecific ADCs accounted for 71% of published applications linked to unique families in 2025, achieving a 23.31% CAGR in novel family publications versus 11.45% for traditional ADCs. This bifurcation in innovation rates reflects where genuine differentiation is occurring—and where patent protection will define competitive positioning over the next decade.

Geographic IP Dynamics

China published the highest absolute number of ADC patent applications in 2025 (2,934), but maintains the lowest grant rate (56%)—consistent with an innovation culture characterized by high-volume early-stage exploration. Japan and Europe each achieved grant rates of approximately 70% despite lower filing volumes, reflecting more selective filing strategies focused on patentability and commercial value.

Europe recorded the strongest YoY growth in 2025 (+41%), while US filings remained essentially flat (+0.4%), suggesting that US-based ADC IP is entering a maturation phase with ongoing lifecycle management rather than rapid new invention.

Target-Level Expiry Risk

As first-generation ADC patents for clinically validated targets approach expiry, the competitive landscape will be substantially reshaped. Near-term expiries are concentrated in HER2 and EGFR—targets with long development histories and intensive first-generation patenting. Notably, HER2 remains heavily defended through successive follow-on filing waves despite early patent expiries, while newer targets such as CDH17 carry minimal near-term expiry risk, offering longer exclusivity windows and greater IP white space for new entrants.

Outlook and Key Industry Implications

Based on the data reviewed above, five structural dynamics will shape ADC R&D and commercial activity in 2026:

Payload Diversification Is No Longer Optional

With topo-1 and tubulin inhibitor-based ADCs approaching saturation in multiple high-value oncology indications, the ability to advance differentiated payload mechanisms—whether kinase inhibitors, BCL-XL antagonists, STING agonists, or splice modulators—will determine which companies attract both licensing partners and investors. Three deals signed in 2025 explicitly reflect this strategic imperative (Synaffix/Qurient, Idience/Abti, Callio/Hummingbird). More are anticipated in 2026.

AOCs Entering a Defining Approval Window

With four AOC candidates (delpacibart zotadirsen, delpacibart braxlosiran, AOC 1001, zeleciment basivarsen) advancing toward BLA/MAA submissions in 2026, this year will produce the first regulatory verdicts on the AOC modality in rare disease. Positive outcomes will substantially accelerate investment into this space; setbacks will require careful contextualization against modality-specific manufacturing and delivery challenges.

Bispecific ADCs Transitioning From Proof-of-Concept to Pivotal Data

With eight BsADC Phase 3 trials initiated in 2025 and multiple additional candidates approaching Phase 3 entry, the field will begin generating pivotal efficacy data in 2026–2027 that will either validate or recalibrate the commercial expectations around bispecific targeting strategies for solid tumors.

Capital Will Concentrate Around Technological Differentiation

The collapse of early-stage financing (from $33B in 2023 to $3B in 2025) and the simultaneous premium valuations paid in late-stage acquisitions (Merus at $8B, Avidity at $12B) suggest that 2026 financing rounds will be heavily bifurcated: companies with validated platforms and Phase 2+ data will attract capital at premium valuations; those without will face constrained access. Platform differentiation—in conjugation chemistry, bispecific engineering, or novel payload mechanisms—is the primary investable attribute.

Emerging Targets Represent the Next Competitive Frontier

CDH17, DLL3, CLDN6, and FGFR2b collectively represent a second-generation target cohort where early clinical data will define market dynamics. With minimal near-term IP expiry risk and significant unmet medical need, these antigens offer both biological differentiation and competitive white space relative to the crowded HER2/TROP2/EGFR landscape.

Frequently Asked Questions